Clinical Trial Detail

NCT ID NCT03391973
Title Pembrolizumab in Patients With Poor-Prognosis Carcinoma of Unknown Primary Site (CUP) (CUP)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors AHS Cancer Control Alberta
Indications

squamous cell carcinoma

adenocarcinoma

carcinoma

Therapies

Pembrolizumab

Age Groups: adult senior

No variant requirements are available.